Profile: Lexicon Pharmaceuticals Inc (LXRX.O)
19 Jul 2019
Lexicon Pharmaceuticals, Inc., incorporated on July 7, 1995, is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. The Company's drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development.
XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. As of December 31, 2016, the Company conducted a third Phase III clinical trial of sotagliflozin, inTandem3, which had completed enrollment of 1,406 patients with type 1 diabetes in a randomized, double-blind, placebo-controlled study of a 400 milligram (mg) once daily dose of sotagliflozin over a 24-week treatment period.
LX2761 is an orally-delivered small molecule compound that the Company is developing for the treatment of diabetes. The Company is conducting a Phase I clinical trial evaluating the safety and tolerability of LX2761. The Phase I trial is a randomized, double-blind, placebo-controlled, ascending single dose study of LX2761 in both healthy volunteers and patients with type 2 diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain. The Company has completed investigational new drug (IND)-enabling studies of LX9211.
The Company competes with Novartis and Ipsen.
Lexicon Pharmaceuticals Inc
8800 Technology Forest Pl
THE WOODLANDS TX 77381-1160